Information  X 
Enter a valid email address

Ergomed plc (ERGO)

  Print   

Monday 01 November, 2021

Ergomed plc

Total Voting Rights

RNS Number : 8168Q
Ergomed plc
01 November 2021
 

 

Total Voting Rights

 

 

Guildford, UK - 1 November 2021 : In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), Ergomed plc (the "Company") announces the following information.

 

The Company's issued share capital as at 31 October 2021 consisted of 49,117,126 ordinary shares of 1p each, none of which were held in treasury.  Each ordinary share in the capital of the Company carries one voting right.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

 

ENDS

 

Enquiries :

 

Ergomed plc     Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman) 

Richard Barfield (Chief Financial Officer) 

 

Numis Securities Limited    Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Matthew O'Dowd (Nominated Adviser) 

James Black (Broker) 

 

Peel Hunt LLP    Tel: +44 (0) 20 7418 8900

James Steel / Dr. Christopher Golden

 

Consilium Strategic Communications   Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal   [email protected]

Angela Gray

 

 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: http://ergomedplc.com .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRMBBPTMTIJBPB

a d v e r t i s e m e n t